XNCR Company Profile and Key Details

Q: Who are the executives of XNCR?

Ms. Jennifer SandozVice President of HRDr. Jeremy Grunstein Ph.D.Senior Vice President of Bus. Devel.Mr. Kirk Rosemark RACSenior Vice President of Regulatory Affairs & Quality AssuranceMs. Celia E. Eckert J.D.Senior Vice President, Gen. Counsel & Corporation Sec.Dr. Nancy Valente M.D.Executive Vice President & Chief Devel. OfficerMr. Charles LilesAssociate Director and Head of Corporation Communications & Investor RelationsDr. Bassil I. Dahiyat Ph.D.Co-Founder, Chief Executive Officer, Pres & DirectorMr. John J. KuchSenior Vice President & Chief Financial OfficerDr. John R. Desjarlais Ph.D.Executive Vice President of Research & Chief Scientific OfficerDr. John R. DesjarlaisSenior Vice President of Research & Chief Scientific OfficerDr. Allen S. Yang M.D., Ph.D.Senior Vice President & Chief Medical OfficerMr. Eric P. KowackSenior Vice President of Program Leadership & Alliance Management

NASDAQ : XNCR

Xencor

$11.22

-0.66-5.56%

At Close 4:00 PM

67.47

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Xencor, Inc. (XNCR) stock declined over -5.56%, trading at $11.22 on NASDAQ, down from the previous close of $11.88. The stock opened at $11.66, fluctuating between $10.97 and $11.73 in the recent session.

Stock Snapshot

11.88

Prev. Close

831.87M

Market Cap

10.97

Day Low

-4.9

P/E Ratio

-2.29

EPS (TTM)

1.05

Cash Flow per Share

11.66

Open

74.14M

Number of Shares

11.73

Day High

90.36%

Free Float in %

10.99

Book Value

895.18K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
May 15, 2026	11.66	11.66	10.97	11.22	895.18K
May 14, 2026	12.32	12.35	11.77	11.88	570.37K
May 13, 2026	12.36	12.47	12.00	12.38	761.92K
May 12, 2026	12.84	13.00	12.40	12.44	664.33K
May 11, 2026	13.01	13.49	12.75	12.79	643.73K
May 08, 2026	12.22	13.16	12.00	12.86	899.51K
May 07, 2026	12.64	13.21	12.10	12.31	936.48K
May 06, 2026	12.93	13.22	12.72	13.01	818.44K
May 05, 2026	13.49	13.82	12.51	12.85	697.43K
May 04, 2026	12.81	13.46	12.80	13.36	1.3M
Apr 30, 2026	11.70	12.04	11.60	11.93	459.38K
Apr 29, 2026	11.88	11.97	11.47	11.62	902.98K
Apr 28, 2026	13.05	13.35	11.89	12.15	1.04M
Apr 27, 2026	12.86	13.56	12.86	13.10	1.12M
Apr 23, 2026	12.84	13.05	12.33	12.45	335.05K
Apr 22, 2026	12.69	13.01	12.51	12.85	629.86K
Apr 21, 2026	12.78	12.78	12.46	12.61	395.68K
Apr 20, 2026	13.11	13.40	12.78	12.80	643.72K
Apr 17, 2026	12.79	13.16	12.74	13.06	845.55K
Apr 16, 2026	12.54	12.61	12.00	12.45	635.49K

Contact Details

Pasadena, CA 91016

United States

https://www.xencor.com 626 305 5900

About Company

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a tumor-targeted antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab that is in Phase II clinical trial to treat neuroendocrine tumors. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104 and XmAb841, which are in Phase I clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase I clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; and Novartis XmAb. It develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; VIR-2482 that is in Phase 1/2 clinical trial to trat influenza A; VIR-7832, which is in Phase 1b/2a trial to treat mild-to-moderate COVID-19; and BMS-986414 + BMS-986413 is in Phase 2/3 NIH ACTIV-2 trial in treating COVID-19. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, mild cognitive impairment, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Monrovia, California.

Stock Peers

ARGX

-22.81-2.77%

argenx SE$799.32 REGN

-14.62-2.05%

Regeneron Pharmaceuticals, Inc.$698.25 UTHR

-7.21-1.25%

United Therapeutics Corporation$568.58 MDGL

-16.2-3.00%

Madrigal Pharmaceuticals, Inc.$523.69 VRTX

-13.46-2.99%

Vertex Pharmaceuticals Incorporated$436.95 PRAX

-2.94-0.85%

Praxis Precision Medicines, Inc.$342.58 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 KRYS

-10.01-3.16%

Krystal Biotech, Inc.$306.29 ALNY

-6.47-2.20%

Alnylam Pharmaceuticals, Inc.$286.98 ASND

-4.99-2.03%

Ascendis Pharma A/S$240.50

Company Overview

Xencor, Inc. (NASDAQ:XNCR) closed at $11.22 USD, losing -$0.66 (-5.56%) from the previous close of $11.88. The stock is currently mid-range between its 52-week high and low $6.92 and $18.69. With a market capitalization of about $831.87 million, Xencor, Inc. is classified as a small-cap and shows market-like volatility (beta ~0.93). Key stats such as the average daily volume over the past year has been around 841.88 thousand shares, in line with its 52-week average. Headquartered in Pasadena, CA, Xencor, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Bassil I. Dahiyat, the company employs approximately 250 people and listed since December 03, 2013. Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases.

Technical Performance

XNCR has shown weak momentum, losing -10.8% over the past week and -14.42% over the past quarter, though year-to-date performance is down -17.44%. Short-term trend indicators are mixed aligned (SMA20 14.25%, SMA50 1.1%, SMA200 18.75%). The stock’s 14-day RSI is 61.27 (firm momentum), while the ATR of 0.86 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -27.5% below its high and over 95.81% above its low. Average 10-day trading volume of 773.75 thousand shares is in line with the 3-month average of 823.26 thousand, indicating normal recent market interest.

Valuation Metrics

Xencor, Inc. trades at a P/E ratio of -4.98, slightly below the S&P 500 average, with a price-to-sales ratio of 8.69 and a price-to-book ratio of 1.67 suggesting the stock is closer to book value. The P/FCF stands at -4.48, also below market averages.

Dividend & Fair Value

Xencor, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$7.72. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Wall Street analysts project EPS growth of -29.09% annually over the next five years. The latest quarter delivered EPS of -$1.71. The next quarter is forecast at -$0.72. Next year's EPS is expected at -$93.57. Analyst sentiment is bullish. Analyst rating data shows there are 12 Strong Buy ratings, 1 Buy ratings, 3 Hold ratings, 0 Sell rating and 1 Strong Sell ratings. Price targets range from $42.00 to $6.00. The high target offers 274.33% upside. The low target suggests -46.52% downside. The mean target is $22.41. This offers 99.73% upside. Xencor, Inc. earnings surprise history is a mixed track record. The quarter that ended May 06, 2026, missed forecasts by 163.08%. The prior quarter beat by -85.94%. Over the last six quarters, Apple has recorded several small beats. These include -23.46% in February 27, 2025.

Shareholding & Insider Activity

Xencor, Inc. has 71.32 million shares outstanding. The public float is 64.45 million shares, elevated short interest at 19.25% of float. This equals 9.61 million shares. The short ratio is 12.91 days. Institutional investors hold 120.84% of the float. Insiders own 1.26%. Ronin Capital, LLC holds 5.01 million shares, STAFFORD JOHN S III has 606.00 thousand shares and Dahiyat Bassil I has 546.32 thousand shares. Over the past six months, insider transactions show net selling. They sold 237.78 thousand shares across 13 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Xencor generated $168.34M in revenue, or $2.78 per share. Gross margin was 93.17%, operating margin -82.36%, and net profit margin -74.90%. Returns are negative, with ROA at -13.23% and ROE at -18.85%.
On valuation metrics, Xencor trades at a P/E of -4.98, P/S of 8.69 and P/B of 1.67. The current ratio is 6.57 and quick ratio is 6.57. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -325.72 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.34, supported by a cash flow-to-debt ratio of -1.06.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Xencor posted revenue of $168.34M, down slightly from $164.58M in the prior quarter. Gross profit was $156.84M (margin 93.17%). Operating income was - $138.64M (margin -82.4%). Net income was- $126.09M (EPS - $2.08).
The company ended the quarter with $593.73M in cash and short-term investments, a total debt of $83.43M, and net debt of $29.64M. Total assets were $952.69M, with equity of $669.13M. Financials further reflected stability, with operating cash flow of $85.11M, free cash flow of $63.86M, and capital expenditures of - $21.25M.

Price Forecast & Outlook

Our AI price prediction model suggests that Xencor, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 4.37%, with price expected at $11.71 by May 29, 2026, within a range of $11.18 to $12.26 3-Month Outlook: Projected rise of 66.13%, reaching $18.64 by August 13, 2026, with a range of $18.21 to $19.12. 1-Year Outlook: Projected gain of 177.36%, with price at $31.12 by May 14, 2027, within a range of $20.16 to $43.80.

Key Takeaways

Xencor, Inc. (NASDAQ:XNCR) shares are down -17.44% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Xencor, Inc. trading at a premium to the broader market with a P/E of -4.98. Analyst sentiment is mixed, with the majority of ratings in Neutral territory and a mean price target of $35.53, suggesting 216.67% upside. Our AI forecast model points to short-term strength (4.37% over two weeks), a medium-term rise (66.13% over three months), and a longer-term gain (177.36% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Xencor, Inc. (XNCR) stock price?

Xencor, Inc. (NASDAQ: XNCR) stock price is $11.22 in the last trading session. During the trading session, XNCR stock reached the peak price of $11.73 while $10.97 was the lowest point it dropped to. The percentage change in XNCR stock occurred in the recent session was -5.56% while the dollar amount for the price change in XNCR stock was - $0.66.

XNCR's industry and sector of operation?

The NASDAQ listed XNCR is part of Biotechnology industry that operates in the broader Healthcare sector. Xencor, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of XNCR?

Ms. Jennifer Sandoz
Vice President of HR
Dr. Jeremy Grunstein Ph.D.
Senior Vice President of Bus. Devel.
Mr. Kirk Rosemark RAC
Senior Vice President of Regulatory Affairs & Quality Assurance
Ms. Celia E. Eckert J.D.
Senior Vice President, Gen. Counsel & Corporation Sec.
Dr. Nancy Valente M.D.
Executive Vice President & Chief Devel. Officer
Mr. Charles Liles
Associate Director and Head of Corporation Communications & Investor Relations
Dr. Bassil I. Dahiyat Ph.D.
Co-Founder, Chief Executive Officer, Pres & Director
Mr. John J. Kuch
Senior Vice President & Chief Financial Officer
Dr. John R. Desjarlais Ph.D.
Executive Vice President of Research & Chief Scientific Officer
Dr. John R. Desjarlais
Senior Vice President of Research & Chief Scientific Officer
Dr. Allen S. Yang M.D., Ph.D.
Senior Vice President & Chief Medical Officer
Mr. Eric P. Kowack
Senior Vice President of Program Leadership & Alliance Management

How XNCR did perform over past 52-week?

XNCR's closing price is 62.14% higher than its 52-week low of $6.92 where as its distance from 52-week high of $18.69 is -39.97%.

How many employees does XNCR have?

Number of XNCR employees currently stands at 250.

Link for XNCR official website?

Official Website of XNCR is: https://www.xencor.com

How do I contact XNCR?

XNCR could be contacted at phone 626 305 5900 and can also be accessed through its website. XNCR operates from 111 West Lemon Avenue, Pasadena, CA 91016, United States.

How many shares of XNCR are traded daily?

XNCR stock volume for the day was 895.18K shares. The average number of XNCR shares traded daily for last 3 months was 841.88K.

What is the market cap of XNCR currently?

The market value of XNCR currently stands at $831.87M with its latest stock price at $11.22 and 74.14M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	250
Beta	0.99
Sales or Revenue	$168.34M
5Y Sales Change%	2.683%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

XNCR Company Profile and Key Details

Xencor

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Dividend & Fair Value

Company Overview

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Valuation Metrics

Key Takeaways

Price Forecast & Outlook